Phototherapy is the only treatment of value in cases of Arias type I congenital nonobstructive, nonhaemolytic jaundice, unresponsive to phenobarbitone administration (Callahan et al., 1970; Gorodischer et al., 1970; Karon et al., 1970; Land et al., 1970; Altay and Say, 1973; Arrowsmith et al., 1975) . However, the daily duration of exposure to light necessary to maintain bilirubin at safe levels may be so long that it interferes with normal parental attention to the infant. Even continuous light therapy may not prevent a gradual rise in serum bilirubin level after a certain age Altay and Say, 1973) . On the other hand, cholestyramine has been found to reduce the amount of phototherapy needed (Arrowsmith et al., 1975 ,mol/l) and conjugated bilirubin 0-6 mg/100 ml (10-3 pmol/l). Hepatic bilirubin UDP-glucuronyltransferase activity, measured in a needle liver biopsy specimen, was nil (control in 15 adult human specimens: 1V06±0-18 ,umol/g per 30 min) (Odievre and Luzeau, 1971 ).
Methods. Bilirubin determinations were made on venous blood samples, by the method described by Michaelsson (1961) . Reserve bilirubin binding capacity was measured by a method using thin-layer chromatography (Trivin et al., 1977) . The patient was examined at regular intervals by the same psychologist with the Brunet-Lezine scale.
Results
The results of unconjugated bilirubin determinations are summarised in the given 18 hours a day, serum bilirubin concentration ranged from 9-0 to 20-4 mg/100 ml (15-4348-8 jtmol/l) (mean of 27 determinations: 16-5 mg/100 ml; 282-2 ,umol/l). Cholestyramine (4 g/day) supplementation to phototherapy was associated with a highly significant fall in serum bilirubin level, ranging from 7-5 to 13-3 mg/100 ml (128-3-227T4 ,mol/l) (mean of 6 determinations: 10-7 mg/100 ml; 183 ,tmol/l) Table, showing that this capacity always ranged between 16-0 to 19-5 mg/100 ml (273 6-333 5 ,umol/l), except for a single measurement of 25-4 mg/100 ml (434 3 ,tmol/l).
Growth remained within normal limits, the patient being last examined at the age of 27 months. Developmental and neurological examinations were also normal; the developmental quotient was 100.
Discussion
Since phototherapy is the only effective means of controlling hyperbilirubinaemia and preventing kernicterus in patients with Crigler-Najjar type I jaundice and must be continued for life, the longterm efficacy and safety of this therapy must be considered. Kernicterus may occur in patients receiving phototherapy because it was started too late, or because the serum bilirubin is not controlled, due to decay in light energy output from fluorescent tubes after 180 hours of use. Superimposed events such as haemolytic episodes may cause a lifethreatening increase in bilirubin production, or may interfere with albumin binding of bilirubin. Further potential hazards include the harmful effects ofphotodegradation products of bilirubin and harmful biological consequences of phototherapy to the skin and other organs. Phototherapy thus must be initiated under circumstances which will allow close monitoring of the serum bilirubin levels. Sequential determinations of reserve binding capacity, which may provide a better index of the risk of kernicterus, were stable in this patient throughout the study. Phototherapy should be limited to the minimum safe period.
In this case cholestyramine administration caused a fall in serum bilirubin levels when first begun, but no rise when therapy was stopped. When restarted the effect was less dramatic but it did coincide with a fall in the duration of phototherapy required. We are thus unable to confirm fully Arrowsmith's assertion (Arrowsmith et al., 1975) 
